Journal of Exotic Pet Medicine
Volume 18, Issue 2 , Pages 146-152 , April 2009

The Treatment of Adrenal Cortical Disease in Ferrets with 4.7-mg Deslorelin Acetate Implants

  • Robert A. Wagner, VMD

      Affiliations

    • Division of Laboratory Animal Resources, Pittsburgh, PA, USA
    • Corresponding Author InformationAddress correspondence to: Robert A. Wagner, VMD, Division of Laboratory Animal Resources, 3500 Terrace St, S1049 BST, University of Pittsburgh, Pittsburgh, PA USA 15261
    • ,
  • Mark R. Finkler, DVM

      Affiliations

    • Roanoke Animal Hospital, Roanoke, VA USA
    • ,
  • Kellie A. Fecteau, PhD

      Affiliations

    • Department of Comparative Medicine (Clinical Endocrinology Service), College of Veterinary Medicine, The University of Tennessee, Knoxville, TN USA
    • ,
  • Tim E. Trigg, PhD

      Affiliations

    • Peptech Animal Health, Macquarie Park, NSW, Australia

References 

  1. Rosenthal KL, Peterson ME. Evaluation of plasma androgens and estradiol concentrations in ferrets with hyperadrenocorticism. J Am Vet Med Assoc. 1996;209:1097–1102
  2. Wagner RA, Dorn DP. Evaluation of serum estradiol concentrations in alopecic ferrets with adrenal gland tumors. J Am Vet Med Assoc. 1994;205:703–707
  3. Rosenthal KL, Peterson ME, Quesenberry KE, et al. Hyperadrenocorticism associated with adrenocortical tumor or nodular hyperplasia of the adrenal gland in ferrets: 50 cases (1987-1991). J Am Vet Med Assoc. 1993;203:271–275
  4. Weiss CA, Scott MV. Clinical aspects and surgical treatment of hyperadrenocorticism in the domestic ferret: 94 cases (1994-1996). J Am Anim Hosp Assoc. 1997;33:487–493
  5. Schoemaker NJ, Schuurmans M, Moorman H, et al. Correlation between age of neutering and age of onset of hyperadrenocorticism in ferrets. J Am Vet Med Assoc. 2000;216:195–197
  6. Shoemaker NJ, Teerdsb KJ, Molc JA, et al. The role of luteinizing hormone in the pathogenesis of hyperadrenocorticism in neutered ferrets. Mol Cell Endocrinol. 2002;197:117–125
  7. Rilianawati , Jukka TP, Zhang FP, et al. Direct luteinizing hormone action triggers adrenocortical tumorigenesis in castrated mice transgenic for the murine inhibin α-subunit promoter/simian virus 40 T-antigen fusion gene. Mol Endocrinol. 1998;12:801–809
  8. Murthy ASK, Brezak MA, Baez AG. Postcastrational adrenal tumors in two strains of mice: morphologic, histochemical, and chromatographic studies. J Natl Cancer Inst. 1970;45:1211–1222
  9. Pabon JE, Li X, Lei ZM, et al. Novel presence of luteinizing hormone releasing hormone levels/chorionic gonadotropins receptors in human adrenal glands. J Clin Endocrinol Metab. 1996;81:2397–2400
  10. Schoemaker NJ, Hawkins MG. Hyperadrenocorticism in Ferrets: Clinical Updates. Assoc Ex An Vet Proceedings. 2007;79–84
  11. Donovan BT, Ter Haar MB. Effects of luteinizing hormone releasing hormone on plasma follicle-stimulating hormone and luteinizing hormone levels in the ferret. J Endocrinol. 1977;73:37–52
  12. Bielinska M, Parviainen H, Porter-Tinge S, et al. Mouse strain susceptibility to gonadectomy-induced adrenocortical tumor formation correlates with the expression of GATA-4 and luteinizing hormone receptor. Endocrinology. 2003;144(9):4123–4133
  13. Bielinska M, Genova E, Boime I, et al. Gonadotropin-induced adrenocortical neoplasia in NU/J nude mice. Endocrinology. 2005;146(9):3975–3984
  14. Bielinska M, Kiiveri S, Parviainen H, et al. Gonadectomy-induced adrenocortical neoplasia in the domestic ferret (Mustela putorius furo) and laboratory mouse. Vet Pathol. 2006;43:97
  15. Olson PN, Mulnix JA, Nett TM. Concentrations of luteinizing hormone and follicle-stimulating hormone in the serum of sexually intact and neutered dogs. Am J Vet Res. 1992;53:762–766
  16. Firth CH, Dunn TB. Tumours of the adrenal gland. IARC Sci Publ. 1994;111:595–609
  17. Huhtaniemi I, Zhang FP, Kero J, et al. Transgenic and knockout mouse models for the study of luteinizing hormone and luteinizing hormone receptor function. Mol Cell Endocrinol. 2002;187:49–56
  18. Matzuk MM, Finegold MJ, Mather JP, et al. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA. 1994;91:8817–8821
  19. Rahman NA, Kananen RK, Paukku T, et al. Transgenic mouse models for gonadal tumorigenesis. Mol Cell Endocrinol. 1998;145:167–174
  20. Schoemaker NJ, van der Hage MH, Flik G, et al. Morphology of the pituitary gland in ferrets (Mustela putorius furo) with hyperadrenocorticism. J Comp Pathol. 2004;130(4):255–265
  21. Hawkins MG. Possible influence of heredity on multiple endocrine neoplasms in ferrets. Exotic DVM. 2007;8(3):35–37
  22. Johnson-Delaney CA. Ferret adrenal disease: 2006 perspective. Exotic DVM. 2007;8(3):31–34
  23. Peterson RA, Kiupel M, Bielinska M, et al. Transcription factor GATA-4 is a marker of anaplasia in adrenocortical neoplasms of the domestic ferret (Mustela putorius furo). Vet Pathol. 2004;41(4):446–449
  24. Bielinska M, Parviainen H, Porter-Tinge S, et al. Mouse strain susceptibility to gonadectomy-induced adrenocortical tumor formation correlates with the expression of GATA-4 and luteinizing hormone receptor. Endocrinology. 2003;144(9):4123–4133
  25. Plosker GL, Brogden RN. Leuprorelin (A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis, and other sex hormone related disorders). Drugs. 1994;48:930–967
  26. Wagner RA, Bailey EM, Schneider JF, et al. Leuprolide acetate treatment of adrenocortical disease in ferrets. J Am Vet Med Assoc. 2001;218(8):1272–1274
  27. Prohaczik A, Kulcsar M, Trigg T, et al. Treatments suppressing ovarian activity in ferrets (Mustela putorius furo). Reprod Dom Anim. 2003;38(4):331
  28. Wagner RA, Piche C, Jochle W, et al. Clinical observations and endocrine response to treatment of adrenal cortical disease in ferrets with GnRH (deslorelin acetate) implants. Am J Vet Res. 2005;66(5):910–914
  29. Herbert CA, Trigg TE. Applications of GnRH in the control and management of fertility in female animals. Anim Reprod Sci. 2006;88:141–153
  30. Trigg TE, Wright PJ, Armour AF, et al. Use of a GnRH analogue implant to produce reversible long-term suppression of reproductive function in male and female domestic dogs. J Reprod Fert Suppl. 2001;57:255–261
  31. Trigg TE, Doyle AG, Walsh JD, et al. A review of advances in the use of the GnRH agonist deslorelin in control of reproduction. Theriogenology. 2006;66(6-7):1507–1512
  32. Munson L, Bauman JE, Asa CS, et al. Efficacy of the GnRH-analogue deslorelin for suppression of the oestrous cycle in cats. J. Reprod Fert Suppl. 2001;57:269–273
  33. Bertschinger HJ, Asa CS, Calle PP, et al. Control of reproduction and sex related behaviour in exotic wild carnivores with the GnRH analogue deslorelin. J Reprod Fert Suppl. 2001;57:275–283
  34. Bertschinger HJ, Trigg TE, Jöchle W, et al. Induction of contraception in some African wild carnivores by downregulation of LH & FSH secretion using the GnRH analogue deslorelin. Reprod Suppl. 2002;60:41–52
  35. Herbert CA, Trigg TE, Renfree MB, et al. Long-term effects of deslorelin implants on reproduction in the female tammar wallaby (Macropus eugenii). Reproduction. 2005;129:361–369
  36. Junaidi A, Williamson PE, Martin GB, et al. Pituitary and testicular endocrine responses to exogenous gonadotrophin-releasing hormone (GnRH) and luteinising hormone in male dogs treated with GnRH agonist implants. Reprod Fertil Dev. 2007;19:891–898
  37. D'Occhio MJ, Aspden WJ. Characteristics of luteinizing hormone (LH) and testosterone secretion, pituitary responses to LH releasing hormone (LHRH) and reproductive function in young bulls receiving the LHRH agonist deslorelin: effect of castration on LH responses to LHRH. Biol Reprod. 1996;54:45–52
  38. Zlotta AR, Schulmann CC. Can survival be prolonged for patients with hormone-resistant prostate cancer?. Lancet. 2001;357:326–327

PII: S1557-5063(08)00203-6

doi: 10.1053/j.jepm.2008.11.003

Journal of Exotic Pet Medicine
Volume 18, Issue 2 , Pages 146-152 , April 2009

Article Tools